Chadds Ford pharma company will make crush-resistant pain drug

    Chadds Ford-based Endo Pharmaceuticals will make its  Opana ER pain drug crush-resistant.

    The move helps reduce the drug’s potential for abuse and has been approved by the FDA, according to the Philadelphia Business Journal.

    Endo will make the transition in 2012, but little else will change. Opana ER will have the same name, color, size, shape, packaging and dosage. The current Opana ER tablets are taken whole and could be potentially fatal if crushed.

    • WHYY thanks our sponsors — become a WHYY sponsor

    WHYY is your source for fact-based, in-depth journalism and information. As a nonprofit organization, we rely on financial support from readers like you. Please give today.

    Want a digest of WHYY’s programs, events & stories? Sign up for our weekly newsletter.

    Together we can reach 100% of WHYY’s fiscal year goal